Topiramate as a disease modifying therapy for Neuropathy
Brief description of study
NN108 Topiramate as a disease
modifying therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)
The
University of Pennsylvania is currently looking for people with Cryptogenic
Sensory Peripheral Neuropathy for a research study conducted by the Network for
Excellence in Neuroscience Clinical Trials (NeuroNEXT). Dr. Gordon Smith
(Virginia Commonwealth University) is leading this national study. The National
Institutes of Health (NIH) is supporting the study.
Detailed description of study
The purpose
of the research study is to learn if the drug topiramate slows the progression
of Cryptogenic Sensory Peripheral Neuropathy (CSPN) (also known as “idiopathic
neuropathy”) and improves quality of life. As part of this study, we will use a
number of assessments and questionnaires to determine if topiramate improves
symptoms of CSPN. There is a one in two chance of receiving the study drug or
placebo pill.
Participants
must be between 18-80 years of age to be in the study, have a diagnosis of
CSPN, have metabolic syndrome, and no history of prior therapy with topiramate.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Neuropathy,Idiopathic Neuropathy,Cryptogenic Sensory Peripheral Neuropathy,CSPN
-
Age: Between 18 Years - 80 Years
-
Gender: All
Participants
must be between 18-80 years of age to be in the study, have a diagnosis of
CSPN, have metabolic syndrome, and no history of prior therapy with topiramate.
Updated on
08 Jul 2023.
Study ID: 832855
